DelveInsight

Beyond's analysis on DelveInsight

• 2026-09-01 — Approval of Merck's oral PCSK9 inhibitor LIPFENDRA and emerging oral competitors signal a high‑growth phase for the PCSK9 inhibitor market
• 2026-07-28 — DelveInsight forecasts the congestive heart failure market to expand at an 8% CAGR through 2036, signaling rising therapeutic and device demand amid an aging population
• 2026-07-20 — The degenerative disc disease therapy market is forecast to expand at about a 19% CAGR to 2036 as regenerative drug candidates move toward clinical testing

Recent news mentioning DelveInsight

• 2026-09-17 — Paroxysmal Nocturnal Hemoglobinuria Market Forecast Upto 2036: 5 Emerging Therapies Poised to Accelerate Market Growth | DelveInsight
• 2026-09-16 — Sjögren's Syndrome Market to Witness Sustained Growth During the Forecast Period (2026-2036) Due to the Development of Targeted Immunotherapies, FcRn Inhibitors, TYK2 Inhibitors, and Cell Therapies | DelveInsight
• 2026-09-16 — Sjögren's Syndrome Market to Witness Sustained Growth During the Forecast Period (2026-2036) Due to the Development of Targeted Immunotherapies, FcRn Inhibitors, TYK2 Inhibitors, and Cell Therapies | DelveInsight
• 2026-09-15 — Myelodysplastic Syndrome Market Set for Strong Growth During the Forecast Period (2026-2036) as Targeted Therapies and Novel Treatment Approaches Reshape the Landscape | DelveInsight
• 2026-09-15 — Myelodysplastic Syndrome Market Set for Strong Growth During the Forecast Period (2026-2036) as Targeted Therapies and Novel Treatment Approaches Reshape the Landscape | DelveInsight
• 2026-09-14 — Bispecifics Market to Gain Momentum During the Forecast Period (2026-2036) with Expanding Pipeline and Increasing Therapeutic Adoption | DelveInsight
• 2026-09-10 — Obesity Market Set for Explosive 27% CAGR Growth by 2036, Fueled by 7 Promising Emerging Therapies | DelveInsight
• 2026-09-09 — Waldenström Macroglobulinemia Market to Gain Momentum During the Forecast Period (2026-2036) Due to Launch of Novel Drug Classes Including BTK Degraders, Non-covalent BTKi, BCL-2 Inhibitors, and Targeted Radiotherapeutics | DelveInsight
• 2026-09-08 — Sarcoidosis Market Forecast: Emerging Therapies and Increasing Disease Awareness to Drive Expansion by 2036 | DelveInsight
• 2026-09-08 — Sarcoidosis Market Forecast: Emerging Therapies and Increasing Disease Awareness to Drive Expansion by 2036 | DelveInsight
• 2026-09-07 — Community-Acquired Bacterial Pneumonia Market Poised for Expansion During the Forecast Period (2026-2036) Amid Rising Antimicrobial Resistance and Therapeutic Advances | DelveInsight
• 2026-09-03 — Osteosarcoma Market is Set to Rise by 2036 as 8 Emerging Therapies Set to Drive Future Growth | DelveInsight

Appears alongside

• CAGR
• FcRn
• TYK2
• BTK
• Merck
• AstraZeneca
• PCSK9
• CAR

Browse the full archive →